logo
Editor's Introduction to this Issue and Guest Editor
Epstein–Barr virus infection and malignancy in solid organ transplant recipients
The Epstein–Barr virus and post-transplant lymphoproliferative disease
Identifying the patient at risk for post-transplant lymphoproliferative disorder
Epstein–Barr virus load monitoring
The diverse pathology of post-transplant lymphoproliferative disorders
The role of antiviral and immunoglobulin therapy in the prevention of Epstein–Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation
Anti-B cell and anti-cytokine therapy for the treatment of post-transplant lymphoproliferative disorder
Interferon and cytotoxic chemotherapy for the treatment of post-transplant lymphoproliferative disorder
Recurrent Epstein–Barr virus associated disease in a cardiac transplant patient